Advertisement
ADVANCED SEARCH

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Caro, J. J. Articles by Migliaccio-Walle, K. Search for Related Content PubMed PubMed Citation Articles by Caro, J. J. Articles by Migliaccio-Walle, K. Related Collections Arrhythmias Drugs: cardiovascular system Stroke

Anticoagulant prophylaxis against stroke in atrial fibrillation

effectiveness in actual practice

From (Caro, Orejuela, Kelley, Speckman, Migliaccio-Walle) Caro Research, Concord, Mass., and (Caro, Flegel) the Division of General Internal Medicine, Royal Victoria Hospital, Montreal, Que.

Abstract

Background: Randomized trials have shown a beneficial effect of anticoagulation with warfarin to prevent stroke in atrial fibrillation. It is not known whether the same effect will be obtained in actual practice. The authors conducted a prospective observational study to evaluate the effect of preventive anticoagulation in patients with atrial fibrillation in 2 practice settings in Montreal.

Methods: Of the 1725 outpatients screened between October 1990 and September 1993 at a community hospital and a university-affiliated hospital, 221 with documented atrial fibrillation were enrolled and followed up for a mean of 27 months. Most (75%) of the patients excluded did not meet the inclusion criteria (because of, for example, an artificial heart valve, mitral stenosis, cardiac transplantation or transient atrial fibrillation); the remainder had not completed enrolment before the end of the study. Following the baseline visit, patients were interviewed by telephone every 6 months, and reported events were confirmed through review of the patients' charts. Hazards for stroke and for stroke and transient ischemic attack (TIA) combined were calculated for each of 4 treatment groups: ASA, warfarin, blended treatment and no treatment, based on the type of anticoagulation therapy patients received during the entire observation period. The blended-treatment group consisted of patients who started on one active therapy and switched to the other or who switched treatments more than once. Corresponding rate ratios (RRs) and 95% confidence intervals (CIs) were calculated with reference to the no-treatment group. Cox proportional hazards analysis was used to adjust for differences in patient characteristics. The rates of bleeding episodes were also analysed.

Results: On average, the study patients were older (71.6 [standard deviation 9.3] years) and had a higher prevalence of underlying heart disease (52.0%) than those in the randomized trials. Nineteen patients had a first stroke: 4 in the ASA group, 4 in the warfarin group, 4 in the blended-treatment group and 7 in the no-treatment group, for rates of 5.2, 1.8, 5.3 and 5.9 per 100 person-years, respectively. Only warfarin was associated with a significantly lower risk of stroke compared with no anticoagulant therapy (RR 0.31, 95% CI 0.09-1.00). A similar protective effect of warfarin was found for stroke and TIA combined (2.3 v. 6.7 per 100 person-years; RR 0.34, 95% CI 0.12-0.99); the effect of ASA and blended treatment was not significantly different from no treatment. The rate per 100 person-years of any bleeding was not significantly higher for any treatment group (ASA 2.5, warfarin 3.4 and blended treatment 3.5) compared with the no-treatment group (1.9). Patients receiving warfarin had a significantly greater risk of any bleeding event than patients not receiving anticoagulant therapy (RR 1.79, 95% CI 1.07-3.00).

Interpretation: The relative effect of anticoagulant therapy with warfarin in preventing stroke in these practice settings was equivalent to that in the randomized trials, although these patients were older and sicker. This preventive treatment is likely to confer additional benefit as it is more widely prescribed.

This article has been cited by other articles:

				R. P. Whitlock, J. S. Healey, and S. J. Connolly Left Atrial Appendage Occlusion Does Not Eliminate the Need for Warfarin Circulation, November 10, 2009; 120(19): 1927 - 1932. [Full Text] [PDF]

				D. E. Singer, G. W. Albers, J. E. Dalen, M. C. Fang, A. S. Go, J. L. Halperin, G. Y. H. Lip, and W. J. Manning Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 546S - 592S. [Abstract] [Full Text] [PDF]

				C. van Walraven, A. Jennings, N. Oake, D. Fergusson, and A. J. Forster Effect of Study Setting on Anticoagulation Control: A Systematic Review and Metaregression Chest, May 1, 2006; 129(5): 1155 - 1166. [Abstract] [Full Text] [PDF]

				E. Birman-Deych, M. J. Radford, D. S. Nilasena, and B. F. Gage Use and Effectiveness of Warfarin in Medicare Beneficiaries With Atrial Fibrillation Stroke, April 1, 2006; 37(4): 1070 - 1074. [Abstract] [Full Text] [PDF]

				D. E. Singer, G. W. Albers, J. E. Dalen, A. S. Go, J. L. Halperin, and W. J. Manning Antithrombotic Therapy in Atrial Fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 429S - 456S. [Abstract] [Full Text] [PDF]

				A. S. Go, E. M. Hylek, Y. Chang, K. A. Phillips, L. E. Henault, A. M. Capra, N. G. Jensvold, J. V. Selby, and D. E. Singer Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation: How Well Do Randomized Trials Translate Into Clinical Practice? JAMA, November 26, 2003; 290(20): 2685 - 2692. [Abstract] [Full Text] [PDF]

				P. Khairy and S. Nattel New insights into the mechanisms and management of atrial fibrillation Can. Med. Assoc. J., October 29, 2002; 167(9): 1012 - 1020. [Abstract] [Full Text] [PDF]

				S. E. Straus, S. R. Majumdar, and F. A. McAlister New Evidence for Stroke Prevention: Scientific Review JAMA, September 18, 2002; 288(11): 1388 - 1395. [Abstract] [Full Text] [PDF]

				A. Evans and L. Kalra Are the Results of Randomized Controlled Trials on Anticoagulation in Patients With Atrial Fibrillation Generalizable to Clinical Practice? Arch Intern Med, June 11, 2001; 161(11): 1443 - 1447. [Abstract] [Full Text] [PDF]

				R. G. Hart Anticoagulation therapy for patients with atrial fibrillation Can. Med. Assoc. J., October 1, 2000; 163(8): 956 - 957. [Full Text] [PDF]

				A. Evans, I. Perez, G. Yu, and L. Kalra Secondary Stroke Prevention in Atrial Fibrillation : Lessons From Clinical Practice Stroke, September 1, 2000; 31(9): 2106 - 2111. [Abstract] [Full Text] [PDF]

				Corrections Can. Med. Assoc. J., April 1, 2000; 162(7): 973 - 973. [Full Text] [PDF]

				J. Sehmer Anticoagulant prophylaxis against stroke Can. Med. Assoc. J., January 1, 2000; 162(1): 12 - 12. [Full Text] [PDF]

				J. Hoey When editors publish in their own journals Can. Med. Assoc. J., November 1, 1999; 161(11): 1412 - 1413. [Full Text] [PDF]

				S. J. Connolly Preventing stroke in atrial fibrillation: Why are so many eligible patients not receiving anticoagulant therapy? Can. Med. Assoc. J., September 1, 1999; 161(5): 533 - 534. [Full Text] [PDF]

HOME	CURRENT ISSUE	PAST ISSUES	COLLECTIONS	HELP	SEARCH
Copyright 1995-1999, Canadian Medical Association. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p) All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.